Browse Categories

Publications by authors named "Dewey Seto"

  • Page 1 of 1
Mavacamten: Initial Insights From the Risk Evaluation and Mitigation Strategy Program.
Matthew W Martinez Dewey Seto Michael Cheung Michele Coiro Niki Patel

JACC Adv

January 2025

View Article and Find Full Text PDF
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program.
Milind Y Desai Dewey Seto Michael Cheung Sonia Afsari Niki Patel

Circ Heart Fail

January 2025

Article Synopsis
  • - Mavacamten is a cardiac myosin inhibitor approved by the FDA specifically for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), requiring monitoring for heart failure and low left ventricular ejection fraction (LVEF) as part of a risk management program.
  • - Data from the mavacamten REMS database, spanning from April 2022 to February 2024, included over 6,000 patients, revealing that 4.6% experienced a decrease in LVEF to below 50%, while 1.3% required hospitalization for heart failure.
  • - A majority of patients remained on the prescribed doses of mavacamten, with significant improvements in heart function observed: 57.
View Article and Find Full Text PDF
Privacy Policy Site Map

© LitMetric 2025. All rights reserved.

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionika04lp668gf2rbdqsj4fpc30fqo3p6f): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once